19:58 , Aug 8, 2019 |  BC Innovations  |  Distillery Techniques

Mouse model of autoimmune encephalitis for screening therapies

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: Animal models Mice injected with GRIN1 and GRIN2B could be used to screen therapies for the autoimmune disorder anti-NMDA receptor encephalitis. In mice, subcutaneous injection of liposomes loaded with rat...
15:06 , Sep 1, 2017 |  BC Week In Review  |  Company News

Janssen gains MDD compound CERC-501 from Cerecor

Cerecor Inc. (NASDAQ:CERC) divested its CERC-501 to the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) for $25 million and up to $20 million in regulatory milestones. Janssen will assume responsibility for ongoing clinical...
17:40 , Mar 17, 2017 |  BC Week In Review  |  Company News

Ataxion, Luc Therapeutics deal

Ataxion will merge with Luc; the newco will retain Luc's name and focus on precision medicine for neurological and psychiatric diseases. Its pipeline includes programs to treat ataxia, schizophrenia and depression, which is being developed...
21:20 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

CERC-301: Ph II Clin301-203 data

Last November, Cerecor reported top-line data from the double-blind, U.S. Phase II Clin301-203 trial in 115 MDD patients showing that adjunctive treatment with 12 and 20 mg oral CERC-301 on days 0 and 7 each...
07:00 , Oct 27, 2016 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Chimeric rat-human NMDA receptors could help guide the development of selective NMDA receptor PAMs for neurological diseases. The chimeric receptors were constructed by replacing the transmembrane or ligand-binding domains of various NMDA...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

CERC-301: Completed Phase II enrollment

Cerecor completed enrollment of 115 patients in the double-blind, placebo-controlled, U.S. Phase II Clin301-203 trial evaluating 12 and 20 mg oral CERC-301 once weekly for 2 weeks. The trial enrolled patients who experienced a severe...
07:00 , Jun 27, 2016 |  BioCentury  |  Emerging Company Profile

Next-gen NMDA

Naurex Inc. spinout Aptinyx Inc. has a discovery platform and preclinical pipeline of oral small molecule NMDA receptor modulators for CNS disorders that could enhance synaptic plasticity and avoid the adverse events associated with NMDA...
07:00 , May 26, 2016 |  BC Innovations  |  Targets & Mechanisms

Dissociating ketamine

For decades, researchers have struggled with the conundrum of how to exploit the antidepressant effects of ketamine without incurring its psychedelic effects. Now, a group from NIH and the University of Maryland has shown that...
08:00 , Dec 10, 2015 |  BC Innovations  |  Product R&D

Spark in the brain

Spark Therapeutics Inc. is expanding beyond eye and blood diseases with its first foray into the brain for the rare neuronal disorder Batten disease, using a gene therapy delivered to the ependymal cells in the...
02:24 , Oct 16, 2015 |  BC Extra  |  Financial News

Cerecor raises $26M in IPO

Cerecor Inc. (NASDAQ:CERCU) lost $0.10 to $6.40 in its first day of trading Thursday after it raised $26 million through the sale of 4 million units at $6.50 in an IPO underwritten by Maxim Group...